Bottacin Wallace Entringer, de Souza Thais Teles, Melchiors Ana Carolina, Reis Walleri Christini Torelli
Postgraduate Program in Pharmaceutical Services and Policies, Federal University of Paraná, Avenida Prefeito Lothário Meissner, 632 - Jardim Botânico, Curitiba, PR, 80210-170, Brazil.
Department of Pharmaceutical Sciences, Federal University of Paraíba, João Pessoa, PB, Brazil.
Int J Clin Pharm. 2025 Apr 18. doi: 10.1007/s11096-025-01906-2.
The increasing adoption of artificial intelligence (AI) in medicines, pharmacotherapy, and pharmaceutical services necessitates clear guidance on reporting standards. While the MedinAI Statement (Bottacin in Int J Clin Pharm, https://doi.org/10.1007/s11096-025-01905-3, 2025) provides core guidelines for reporting AI studies in these fields, detailed explanations and practical examples are crucial for optimal implementation. This companion document was developed to offer comprehensive guidance and real-world examples for each guideline item. The document elaborates on all 14 items and 78 sub-items across four domains: core, ethical considerations in medication and pharmacotherapy, medicines as products, and services related to medicines and pharmacotherapy. Through clear, actionable guidance and diverse examples, this document enhances MedinAI's utility, enabling researchers and stakeholders to improve the quality and transparency of AI research reporting across various contexts, study designs, and development stages.
人工智能（AI）在医学、药物治疗和药学服务中的应用日益广泛，因此有必要对报告标准提供明确的指导。虽然《MedinAI声明》（Bottacin发表于《国际临床药学杂志》，https://doi.org/10.1007/s11096-025-01905-3，2025年）为这些领域的人工智能研究报告提供了核心指南，但详细的解释和实际例子对于最佳实施至关重要。本配套文件旨在为每个指南项目提供全面的指导和实际例子。该文件详细阐述了四个领域的所有14项和78个子项：核心内容、药物治疗和药物疗法中的伦理考量、药品产品以及与药物和药物疗法相关的服务。通过清晰、可操作的指导和多样的例子，本文档增强了MedinAI的实用性，使研究人员和利益相关者能够在各种背景、研究设计和开发阶段提高人工智能研究报告的质量和透明度。
